Baseline characteristics by TID (none/mild vs. moderate/severe)
| None/Mild TID | Moderate/Severe TID | p-value | |
|---|---|---|---|
| (n=118) | (n=39) | ||
| Age, median (IQR), years | 26 (17, 37) | 41 (25, 53) | <0.001 |
| Men, n (%) | 21 (18) | 10 (26) | 0.29 |
| Black Race, n (%) | 55 (47) | 22 (56) | 0.29 |
| Hispanic ethnicity, n (%) | 41 (40) | 12 (38) | 0.79 |
| Charlson comorbidity index, median (IQR) | 3 (1, 4) | 3 (1, 4) | 0.09 |
| Creatinine (mg/dL), median (IQR) | 0.8 (0.6, 1.2) | 1.6 (1, 2.6) | <0.001 |
| eGFR mL/min/1.73m2, median (IQR) | 91 (61, 127) | 42 (26, 75) | <0.001 |
| Protein/Creatinine ratio (mg/mg), median (IQR) | 2.2 (1.0, 4.9) | 2.1 (1.5, 5.5) | 0.68 |
| LN class n (%) | 0.008 | ||
| I/II | 10 (9) | 0 | |
| III/IV ± V | 71 (61) | 34 (87) | |
| V | 35 (30) | 5 (13) | |
| Low C3, n (%) | 83 (75) | 23 (70) | 0.51 |
| Low C4, n (%) | 76 (70) | 22 (67) | 0.69 |
| Elevated dsDNA, n (%) | 70 (68) | 21 (66) | 0.81 |
| Anti-Ro, n (%) | 55 (47) | 17 (44) | 0.74 |
| Anti-Ro and anti-La, n (%) | 11 (9) | 11 (28) | 0.003 |